Differential effects of hypoxia on motility using various in vitro models of lung adenocarcinoma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 09 2024
03 09 2024
Historique:
received:
20
02
2024
accepted:
21
08
2024
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
3
9
2024
Statut:
epublish
Résumé
Lung cancer is the leading cause of cancer-related death globally. Metastasis is the most common reason of mortality in which hypoxia is suggested to have a pivotal role. However, the effect of hypoxia on the metastatic potential and migratory activity of cancer cells is largely unexplored and warrants detailed scientific investigations. Accordingly, we analyzed changes on cell proliferation and migratory activity both in single-cell migration and invasion under normoxic and hypoxic conditions in lung adenocarcinoma cell lines. Alterations in crucial genes and proteins associated with cellular response to hypoxia, epithelial-mesenchymal transition, proliferation and apoptosis were also analyzed. Generally, we observed no change in proliferation upon hypoxic conditions and no detectable induction of apoptosis. Interestingly, we observed that single-cell motility was generally reduced while invasion under confluent conditions using scratch assay was enhanced by hypoxia in most of the cell lines. Furthermore, we detected changes in the expression of EMT markers that are consistent with enhanced motility and metastasis-promoting effect of hypoxia. In summary, our study indicated cell line-, time of exposure- and migrational type-dependent effects of hypoxia in cellular proliferation, motility and gene expression. Our results contribute to better understanding and tackling cancer metastasis.
Identifiants
pubmed: 39227650
doi: 10.1038/s41598-024-70769-w
pii: 10.1038/s41598-024-70769-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20482Subventions
Organisme : Nemzeti Kutatási, Fejlesztési és Innovaciós Alap
ID : KDP-2020-1018567
Organisme : Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
ID : TKP2021-EGA-44
Informations de copyright
© 2024. The Author(s).
Références
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249. https://doi.org/10.3322/caac.21660 (2021).
doi: 10.3322/caac.21660
pubmed: 33538338
Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E. & Adjei, A. A. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83, 584–594. https://doi.org/10.4065/83.5.584 (2008).
doi: 10.4065/83.5.584
pubmed: 18452692
Zarogoulidis, P. et al. Effective early diagnosis for NSCLC: An algorithm. Expert Rev. Respir. Med. 15, 1437–1445. https://doi.org/10.1080/17476348.2021.1969916 (2021).
doi: 10.1080/17476348.2021.1969916
pubmed: 34403620
Nichols, L., Saunders, R. & Knollmann, F. D. Causes of death of patients with lung cancer. Arch. Pathol. Lab. Med. 136, 1552–1557. https://doi.org/10.5858/arpa.2011-0521-OA (2012).
doi: 10.5858/arpa.2011-0521-OA
pubmed: 23194048
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646–674. https://doi.org/10.1016/j.cell.2011.02.013 (2011).
doi: 10.1016/j.cell.2011.02.013
pubmed: 21376230
Muz, B., de la Puente, P., Azab, F. & Azab, A. K. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckland) 3, 83–92. https://doi.org/10.2147/HP.S93413 (2015).
doi: 10.2147/HP.S93413
McKeown, S. R. Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. Br. J. Radiol. 87, 20130676. https://doi.org/10.1259/bjr.20130676 (2014).
doi: 10.1259/bjr.20130676
pubmed: 24588669
pmcid: 4064601
Le, Q. T. et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin. Cancer Res. 12, 1507–1514. https://doi.org/10.1158/1078-0432.CCR-05-2049 (2006).
doi: 10.1158/1078-0432.CCR-05-2049
pubmed: 16533775
Saxena, K. & Jolly, M. K. Acute vs. chronic vs. cyclic hypoxia: Their differential dynamics, molecular mechanisms, and effects on tumor progression. Biomolecules https://doi.org/10.3390/biom9080339 (2019).
doi: 10.3390/biom9080339
pubmed: 31382593
pmcid: 6722594
Liu, Q., Palmgren, V. A. C., Danen, E. H. & Le Devedec, S. E. Acute vs. chronic vs. intermittent hypoxia in breast cancer: A review on its application in in vitro research. Mol. Biol. Rep. 49, 10961–10973. https://doi.org/10.1007/s11033-022-07802-6 (2022).
doi: 10.1007/s11033-022-07802-6
pubmed: 36057753
pmcid: 9618509
Semenza, G. L. & Wang, G. L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell Biol. 12, 5447–5454. https://doi.org/10.1128/mcb.12.12.5447-5454.1992 (1992).
doi: 10.1128/mcb.12.12.5447-5454.1992
pubmed: 1448077
pmcid: 360482
Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271–275. https://doi.org/10.1038/20459 (1999).
doi: 10.1038/20459
pubmed: 10353251
Al Tameemi, W., Dale, T. P., Al-Jumaily, R. M. K. & Forsyth, N. R. Hypoxia-modified cancer cell metabolism. Front. Cell Dev. Biol. 7, 4. https://doi.org/10.3389/fcell.2019.00004 (2019).
doi: 10.3389/fcell.2019.00004
pubmed: 30761299
pmcid: 6362613
Berchner-Pfannschmidt, U., Frede, S., Wotzlaw, C. & Fandrey, J. Imaging of the hypoxia-inducible factor pathway: Insights into oxygen sensing. Eur. Respir. J. 32, 210–217. https://doi.org/10.1183/09031936.00013408 (2008).
doi: 10.1183/09031936.00013408
pubmed: 18591338
Mole, D. R. et al. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J. Biol. Chem. 284, 16767–16775. https://doi.org/10.1074/jbc.M901790200 (2009).
doi: 10.1074/jbc.M901790200
pubmed: 19386601
pmcid: 2719312
Tirpe, A. A., Gulei, D., Ciortea, S. M., Crivii, C. & Berindan-Neagoe, I. Hypoxia: Overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes. Int. J. Mol. Sci https://doi.org/10.3390/ijms20246140 (2019).
doi: 10.3390/ijms20246140
pubmed: 31817513
pmcid: 6941045
Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178–196. https://doi.org/10.1038/nrm3758 (2014).
doi: 10.1038/nrm3758
pubmed: 24556840
pmcid: 4240281
Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442–454. https://doi.org/10.1038/nrc822 (2002).
doi: 10.1038/nrc822
pubmed: 12189386
Friedl, P. & Wolf, K. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat. Rev. Cancer 3, 362–374. https://doi.org/10.1038/nrc1075 (2003).
doi: 10.1038/nrc1075
pubmed: 12724734
Tatrai, E. et al. Cell type-dependent HIF1 alpha-mediated effects of hypoxia on proliferation, migration and metastatic potential of human tumor cells. Oncotarget 8, 44498–44510. https://doi.org/10.18632/oncotarget.17806 (2017).
doi: 10.18632/oncotarget.17806
pubmed: 28562340
pmcid: 5546497
Liu, T. et al. Regulation of vimentin intermediate filaments in endothelial cells by hypoxia. Am. J. Physiol. Cell Physiol. 299, C363-373. https://doi.org/10.1152/ajpcell.00057.2010 (2010).
doi: 10.1152/ajpcell.00057.2010
pubmed: 20427712
pmcid: 2928624
Maier, J., Traenkle, B. & Rothbauer, U. Real-time analysis of epithelial-mesenchymal transition using fluorescent single-domain antibodies. Sci. Rep. 5, 13402. https://doi.org/10.1038/srep13402 (2015).
doi: 10.1038/srep13402
pubmed: 26292717
pmcid: 4544033
Salem, A. et al. Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome. J. Natl. Cancer Inst. https://doi.org/10.1093/jnci/djx160 (2018).
doi: 10.1093/jnci/djx160
pubmed: 28922791
Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J Clin 73, 17–48. https://doi.org/10.3322/caac.21763 (2023).
doi: 10.3322/caac.21763
pubmed: 36633525
Giatromanolaki, A. et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br. J. Cancer 85, 881–890. https://doi.org/10.1054/bjoc.2001.2018 (2001).
doi: 10.1054/bjoc.2001.2018
pubmed: 11556841
pmcid: 2375073
Wu, X. H., Qian, C. & Yuan, K. Correlations of hypoxia-inducible factor-1alpha/hypoxia-inducible factor-2alpha expression with angiogenesis factors expression and prognosis in non-small cell lung cancer. Chin. Med. J. (England) 124, 11–18 (2011).
Keith, B., Johnson, R. S. & Simon, M. C. HIF1alpha and HIF2alpha: Sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 12, 9–22. https://doi.org/10.1038/nrc3183 (2011).
doi: 10.1038/nrc3183
pubmed: 22169972
pmcid: 3401912
Semenza, G. L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit. Rev. Biochem. Mol. Biol. 35, 71–103. https://doi.org/10.1080/10409230091169186 (2000).
doi: 10.1080/10409230091169186
pubmed: 10821478
Nisar, H. et al. Hypoxia changes energy metabolism and growth rate in non-small cell lung cancer cells. Cancers (Basel) https://doi.org/10.3390/cancers15092472 (2023).
doi: 10.3390/cancers15092472
pubmed: 37173939
Wang, X. & Schneider, A. HIF-2alpha-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia. Carcinogenesis 31, 1202–1210. https://doi.org/10.1093/carcin/bgq078 (2010).
doi: 10.1093/carcin/bgq078
pubmed: 20395290
pmcid: 2893799
Shi, R., Liao, C. & Zhang, Q. Hypoxia-driven effects in cancer: Characterization, mechanisms, and therapeutic implications. Cells https://doi.org/10.3390/cells10030678 (2021).
doi: 10.3390/cells10030678
pubmed: 35011587
pmcid: 8750352
Naveena, H. A. & Bhatia, D. Hypoxia modulates cellular endocytic pathways and organelles with enhanced cell migration and 3D cell invasion. Chembiochem 24, e202300506. https://doi.org/10.1002/cbic.202300506 (2023).
doi: 10.1002/cbic.202300506
Wang, T. et al. Hypoxia increases the motility of lung adenocarcinoma cell line A549 via activation of the epidermal growth factor receptor pathway. Cancer Sci. 98, 506–511. https://doi.org/10.1111/j.1349-7006.2007.00428.x (2007).
doi: 10.1111/j.1349-7006.2007.00428.x
pubmed: 17425591
pmcid: 11160049
Lehmann, S. et al. Hypoxia induces a HIF-1-dependent transition from collective-to-amoeboid dissemination in epithelial cancer cells. Curr. Biol. 27, 392–400. https://doi.org/10.1016/j.cub.2016.11.057 (2017).
doi: 10.1016/j.cub.2016.11.057
pubmed: 28089517
Kataoka, Y. et al. Hypoxia-induced galectin-3 enhances RhoA function to activate the motility of tumor cells in non-small cell lung cancer. Oncol. Rep. 41, 853–862. https://doi.org/10.3892/or.2018.6915 (2019).
doi: 10.3892/or.2018.6915
pubmed: 30535445
Liu, K. H. et al. Hypoxia stimulates the epithelial-to-mesenchymal transition in lung cancer cells through accumulation of nuclear beta-catenin. Anticancer Res. 38, 6299–6308. https://doi.org/10.21873/anticanres.12986 (2018).
doi: 10.21873/anticanres.12986
pubmed: 30396950
Yan, F. et al. Hypoxia promotes non-small cell lung cancer cell stemness, migration, and invasion via promoting glycolysis by lactylation of SOX9. Cancer Biol. Ther. 25, 2304161. https://doi.org/10.1080/15384047.2024.2304161 (2024).
doi: 10.1080/15384047.2024.2304161
pubmed: 38226837
pmcid: 10793688
Hui, L. et al. Prognostic significance of twist and N-cadherin expression in NSCLC. PLoS ONE 8, e62171. https://doi.org/10.1371/journal.pone.0062171 (2013).
doi: 10.1371/journal.pone.0062171
pubmed: 23626784
pmcid: 3633889
Li, X., Combs, J. D. 3rd., Salaita, K. & Shu, X. Polarized focal adhesion kinase activity within a focal adhesion during cell migration. Nat. Chem. Biol. 19, 1458–1468. https://doi.org/10.1038/s41589-023-01353-y (2023).
doi: 10.1038/s41589-023-01353-y
pubmed: 37349581
pmcid: 10732478
Shen, C. et al. Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene. Cancer Discov. 1, 222–235. https://doi.org/10.1158/2159-8290.CD-11-0098 (2011).
doi: 10.1158/2159-8290.CD-11-0098
pubmed: 22037472
pmcid: 3202343
Velasco-Hernandez, T., Hyrenius-Wittsten, A., Rehn, M., Bryder, D. & Cammenga, J. HIF-1alpha can act as a tumor suppressor gene in murine acute myeloid leukemia. Blood 124, 3597–3607. https://doi.org/10.1182/blood-2014-04-567065 (2014).
doi: 10.1182/blood-2014-04-567065
pubmed: 25267197
Tiwari, A. et al. Loss of HIF1A from pancreatic cancer cells increases expression of PPP1R1B and degradation of p53 to promote invasion and metastasis. Gastroenterology 159(1882–1897), e1885. https://doi.org/10.1053/j.gastro.2020.07.046 (2020).
doi: 10.1053/j.gastro.2020.07.046
Hegedus, L. et al. HDAC inhibition induces PD-L1 expression in a novel anaplastic thyroid cancer cell line. Pathol. Oncol. Res. 26, 2523–2535. https://doi.org/10.1007/s12253-020-00834-y (2020).
doi: 10.1007/s12253-020-00834-y
pubmed: 32591993
Baranyi, M. et al. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors. Br. J. Cancer https://doi.org/10.1038/s41416-024-02586-x (2024).
doi: 10.1038/s41416-024-02586-x
pubmed: 38278976
pmcid: 10951297
Suarez-Arnedo, A. et al. An image J plugin for the high throughput image analysis of in vitro scratch wound healing assays. PLoS ONE 15, e0232565. https://doi.org/10.1371/journal.pone.0232565 (2020).
doi: 10.1371/journal.pone.0232565
pubmed: 32722676
pmcid: 7386569